NYXH Stock Overview
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Nyxoah S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €12.35 |
52 Week High | €17.60 |
52 Week Low | €3.79 |
Beta | 0.49 |
1 Month Change | -22.57% |
3 Month Change | 185.88% |
1 Year Change | 91.18% |
3 Year Change | -36.67% |
5 Year Change | n/a |
Change since IPO | -36.67% |
Recent News & Updates
Shareholder Returns
NYXH | BE Medical Equipment | BE Market | |
---|---|---|---|
7D | -21.8% | -0.8% | 2.9% |
1Y | 91.2% | 14.2% | -1.0% |
Return vs Industry: NYXH exceeded the Belgian Medical Equipment industry which returned 12.8% over the past year.
Return vs Market: NYXH exceeded the Belgian Market which returned -1.9% over the past year.
Price Volatility
NYXH volatility | |
---|---|
NYXH Average Weekly Movement | 22.9% |
Medical Equipment Industry Average Movement | 5.5% |
Market Average Movement | 3.6% |
10% most volatile stocks in BE Market | 7.2% |
10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: NYXH's share price has been volatile over the past 3 months.
Volatility Over Time: NYXH's weekly volatility has increased from 13% to 23% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 138 | Olivier Taelman | https://www.nyxoah.com |
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A. Fundamentals Summary
NYXH fundamental statistics | |
---|---|
Market cap | €354.12m |
Earnings (TTM) | -€43.21m |
Revenue (TTM) | €4.35m |
81.4x
P/S Ratio-8.2x
P/E RatioIs NYXH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NYXH income statement (TTM) | |
---|---|
Revenue | €4.35m |
Cost of Revenue | €1.66m |
Gross Profit | €2.69m |
Other Expenses | €45.90m |
Earnings | -€43.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 02, 2024
Earnings per share (EPS) | -1.51 |
Gross Margin | 61.91% |
Net Profit Margin | -993.84% |
Debt/Equity Ratio | 8.9% |
How did NYXH perform over the long term?
See historical performance and comparison